StockData
SCYNEXIS Inc logo

SCYNEXIS Inc (SCYX) stock

SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3076% below fair value
$2.38−0.23 (-8.64%)

Close on Nov 20, 2026Market cap $23.68MP/E –Yield –

Scynexis free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Scynexis's free cash flow for the twelve months ending Dec 31, 2021 was -$54.56M. For fiscal 2021 it was -$54.56M. The highest annual figure on record is -$4.74M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2021Dec 31, 2021-$54.56M–
FY2020Dec 31, 2020-$49.36M–
FY2019Dec 31, 2019-$38.12M–
FY2018Dec 31, 2018-$28.89M–
FY2017Dec 31, 2017-$24.56M–
FY2016Dec 31, 2016-$29.38M–
FY2015Dec 31, 2015-$25.13M–
FY2014Dec 31, 2014-$10.18M–
FY2013Dec 31, 2013-$4.74M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021-$25.52M–
Q3 FY2021Sep 30, 2021-$16.59M–
Q2 FY2021Jun 30, 2021-$11.70M–
Q1 FY2021Mar 31, 2021-$759.00K–
Q4 FY2020Dec 31, 2020-$16.57M–
Q3 FY2020Sep 30, 2020-$9.87M–
Q2 FY2020Jun 30, 2020-$8.86M–
Q1 FY2020Mar 31, 2020-$14.06M–
Q4 FY2019Dec 31, 2019-$13.46M–
Q3 FY2019Sep 30, 2019-$10.40M–
Q2 FY2019Jun 30, 2019-$7.76M–
Q1 FY2019Mar 31, 2019-$6.50M–
Q4 FY2018Dec 31, 2018-$6.15M–
Q3 FY2018Sep 30, 2018-$6.22M–
Q2 FY2018Jun 30, 2018-$8.30M–
Q1 FY2018Mar 31, 2018-$8.23M–
Q4 FY2017Dec 31, 2017-$5.16M–
Q3 FY2017Sep 30, 2017-$5.25M–
Q2 FY2017Jun 30, 2017-$7.38M–
Q1 FY2017Mar 31, 2017-$6.77M–
Q4 FY2016Dec 31, 2016-$4.56M–
Q3 FY2016Sep 30, 2016-$6.86M–

More Scynexis figures

See a number that looks wrong?